Genmab A/S has entered a partnership with AI research company Anthropic to boost its research and development capabilities. The collaboration, announced on January 7, will utilize agentic AI powered by Claude models to automate complex data processing and document creation while maintaining human oversight.
According to Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer, this move aims to create a more scalable, effective, and digitally enabled R&D process. Genmab is a biotechnology company focused on oncology, developing antibody-based therapies for cancer treatment, with late-stage pipeline programs including Rina‑S and Epkinly.
On January 8, TheFly reported that Deutsche Bank raised its price target for Genmab's stock, traded as GMAB on NASDAQ, to DKK 2,400 from DKK 2,000, while reiterating a Buy rating. This adjustment reflects analysts' optimism regarding the company's late-stage oncology pipeline.